Rimegepant

Rimegepant is a prescription migraine tablet sold in the United States under the brand name Nurtec ODT. It belongs to a drug class called calcitonin gene-related peptide receptor antagonists, better known as gepants. US labeling approves it for two jobs in adults: treating a migraine attack that has already started, and preventing episodic migraine.

The tablet is an orally disintegrating tablet, which means it dissolves on the tongue without water. That detail matters during an attack, when nausea makes swallowing a pill unpleasant. It is also prescribed for people who cannot use triptans, the older acute migraine drugs, because of heart or blood vessel concerns. This page explains what the labeling covers, what can go wrong, how the drug compares with other options, and what drives the bill when you pay cash. Other drug references are collected in the Medication Index.

How rimegepant works in the body

Calcitonin gene-related peptide, usually shortened to CGRP, is a small protein released around nerves and blood vessels in the head. During a migraine attack, CGRP levels rise. It widens blood vessels and turns up pain signalling in the trigeminal nerve system, which is why an attack can feel like pressure, throbbing and light sensitivity all at once.

This medicine blocks the receptor that CGRP plugs into. If the signal cannot land, the pain cascade is dampened. That is a different approach from triptans, which act on serotonin receptors and narrow blood vessels. Gepants do not rely on narrowing vessels, and that difference shapes who can safely take them.

Because it is taken by mouth and absorbed through the gut, it does not work instantly. In the pivotal acute treatment trial published in a major medical journal, more adults who took a single dose were free of pain at the two hour mark than those who took placebo, and more had relief from their most bothersome symptom, such as nausea or light sensitivity. You can read the randomised trial of oral rimegepant for acute migraine for the full design and results. A later journal review summarised both the acute and preventive evidence in one place, including a clinical review of the drug in migraine care.

What the label approves it for, and how it is taken

The approved uses are narrow and specific. First, acute treatment of migraine with or without aura in adults. Aura means the visual or sensory warning signs some people get before or during an attack. Second, preventive treatment of episodic migraine in adults. Episodic migraine generally means fewer than 15 headache days a month; 15 or more days a month for at least three months is usually classed as chronic migraine, which this labeling does not cover.

Both uses sit in the same product, which is unusual. Most migraine drugs are either rescue treatments or daily preventives, not both.

Dosing differs between the two uses, and only your prescriber can decide which applies to you. Labeling describes a single 75 mg orally disintegrating tablet for an attack, with no more than one dose in 24 hours, and a 75 mg tablet every other day for prevention of episodic migraine. Labeling also caps total use at 18 doses in any 30 day period. Those numbers come straight from the manufacturer’s full prescribing information for rimegepant tablets, and the prescription you are given always overrides a web page. A plain-language summary for patients is kept at the MedlinePlus drug information page.

It is a prescription-only medicine in the United States. It is not a controlled substance, which is one reason telehealth clinicians can prescribe it more freely than, say, a stimulant or an opioid.

Side effects: common, rare and serious

The most commonly reported side effect of rimegepant in clinical trials was nausea. Stomach pain and indigestion were also reported. For most people in studies these effects were mild and did not lead to stopping treatment. Feeling sleepy or getting a tingling sensation, both familiar to triptan users, are not typical features of this drug.

The serious risk to know about is an allergic reaction. Labeling warns that severe hypersensitivity reactions have happened, including anaphylaxis, difficulty breathing and rash. Crucially, these reactions can appear days after a dose, not only minutes later. That is unusual and worth remembering: a new rash, facial swelling, throat tightness or breathing trouble in the days after taking a dose is a reason to stop and get medical help, not to wait and see.

Newer labeling also flags two effects that show up across the gepant class. New or worsening high blood pressure may occur. So may new or worsening Raynaud’s phenomenon, where fingers or toes go white, blue and numb in the cold because small blood vessels overreact.

On long-term use, the published safety picture comes from open-label studies that followed adults taking the preventive schedule for up to a year. Reported adverse events stayed broadly in line with the shorter trials, and no liver toxicity signal of the kind that sank an earlier generation of gepants was identified. That is reassuring rather than final. Report anything new to the clinician who prescribed it, and check the current label for updates before you assume a side effect is not related.

Warnings, contraindications and drug interactions

There is one absolute contraindication in the labeling: known hypersensitivity to the drug or to any of its ingredients. If you have had a reaction to it before, you should not take it again.

Beyond that, several groups need care. Labeling advises against use in people with severe liver impairment, because blood levels rise substantially. It also advises against use in people with severe kidney impairment. Pregnancy and breastfeeding are open questions: there is not enough human data to characterise risk, so the decision belongs in a conversation with your own clinician rather than in a general guide. These points are set out in the FDA-approved prescribing information and mirrored on the DailyMed label database.

Drug interactions are the part patients most often miss, because they involve ordinary medicines. The drug is processed by a liver enzyme called CYP3A4 and moved by transporters called P-gp and BCRP. That creates four practical rules in the labeling:

• Avoid using it with strong CYP3A4 inhibitors, a group that includes some antifungal and antiviral drugs and the antibiotic clarithromycin.
• With moderate CYP3A4 inhibitors, avoid a second dose within 48 hours.
• Avoid strong or moderate CYP3A4 inducers, including rifampin, some anti-seizure drugs and the supplement St John’s wort, because they can push drug levels down and blunt the effect.
• Avoid inhibitors of P-gp or BCRP, which include certain heart rhythm and transplant medicines.

Bring a full list of everything you take, prescription and non-prescription, to the appointment. Supplements count. So do other migraine treatments: stacking two CGRP drugs, or leaning on any acute migraine medicine too many days a month, is a route to medication overuse headache, which makes the underlying problem worse.

Because raised blood pressure is now a labeled precaution, it helps to know your own numbers rather than guess. Home readings taken over several days are far more useful to a clinician than a single cuff reading in a clinic.

Rimegepant compared with triptans and other migraine drugs

Patients searching for this drug are usually weighing it against sumatriptan or rizatriptan, the two most widely prescribed triptans. They are not the same drug and not the same class. Both classes are used to stop attacks, but they work on different targets and carry different cautions. Neither is a universal winner; the right choice depends on your medical history and how you have responded before.

Two practical points follow from that table. If you have significant heart or stroke history, the vascular caution attached to triptans is the reason a clinician may reach for a gepant instead. If cost is the binding constraint and you have no vascular history, an established generic triptan is usually the cheaper first attempt, which is exactly why many insurers ask you to try one first. A UK patient charity keeps a readable overview of the gepant class that is useful background, though prescribing rules differ outside the United States.

Other options in the same conversation include ubrogepant and atogepant, injectable CGRP antibodies given monthly or quarterly, and older preventives such as beta blockers, certain antidepressants and anti-seizure drugs. General migraine background is collected on the MedlinePlus migraine health topic.

What it costs when you pay cash

Cost is the reason most people land on a page like this. Two payment routes exist and they should never be blended. Cash pay means what you hand over yourself with no plan involved. With insurance means the plan or membership fee only, and it excludes copays and deductibles, which vary by plan and by state.

All figures on this site are US dollars per month, and prices move, so the number below is pulled live rather than typed into the text. Across the self-pay programs tracked for rimegepant, the lowest recurring monthly price is and the median is .

Several things move that number:

• Brand versus generic. Whether a lower cost generic version is stocked at a given pharmacy changes over time. Ask the pharmacist to check both the brand and any generic listing before you accept the first quote.
• Doses per box. Acute use and preventive use consume very different quantities per month, so a per-tablet price and a monthly price can tell two different stories.
• What the fee includes. Some telehealth programs bundle the clinician visit, messaging and follow-up into one monthly charge, with medication billed separately by the pharmacy. Others quote medication and visit together. Read what is inside the number.
• Intro versus renewal pricing. A first month discount that resets later is common. Compare the renewal rate, not the hook.

On the insurance side, be realistic. Gepants are frequently placed behind prior authorization or step therapy, meaning a plan may want documentation that triptans failed or were unsuitable first. Nothing here promises coverage. Check your own formulary, then confirm with your plan in writing. If you want to see which programs can bill a given payer, the collections for Providers That Bill Medicare and for Cash Pay Programs are browseable lists, not coverage guarantees.

If you are comparing a monthly self-pay program against an insured route, the yearly total is the honest comparison, because a small monthly gap compounds.

For a worked example of how the cost side of a program is laid out, see the Sample Savings Report, and the interactive Health Calculators Hub collects the rest of the estimators.

Getting a prescription through a telehealth program

Migraine is one of the conditions telemedicine handles reasonably well, because diagnosis leans on history rather than hands-on examination. Still, programs differ more than their marketing suggests, and rimegepant is not something every general telehealth service will prescribe. Things worth comparing before you pay anything:

1. Does the program actually treat migraine? Some platforms only cover a fixed condition list. Headache care is often absent.
2. Who reviews your history? Look for a licensed clinician who takes a real headache history, asks about attack frequency, other medicines and blood pressure, and screens for red flags rather than running a two minute form.
3. Acute, preventive or both? A program set up for rescue prescriptions may not manage a preventive schedule, or vice versa.
4. Where the prescription goes. Local pharmacy pickup suits an acute treatment you may need at short notice; mail order suits a steady preventive routine.
5. Follow-up and refills. Ask how often you will be reassessed, whether messaging is included, and what happens if the drug does not help.
6. State licensure. Prescribing rules are set state by state, so availability varies by where you live.

You can browse programs and patient ratings in the Telehealth Provider Directory, and the Scoring Methodology page sets out how the comparison dimensions are weighted.

Questions to ask, and when to get urgent help

Come to the appointment with these written down. Is this for stopping attacks, preventing them, or both? Given my heart, blood pressure and stroke history, is a gepant or a triptan the better fit? Which of my current medicines or supplements interact with it? How many days a month can I safely treat before medication overuse becomes a risk? What should I do if a dose does not work? What is the plan if I get a rash or breathing trouble days later? And what does the whole month cost me, including the pharmacy charge?

Some headaches need emergency care, not a prescription refill. Seek urgent medical help for a sudden severe headache that peaks within seconds, the worst headache of your life, a headache with fever and a stiff neck, or a headache with weakness, numbness, slurred speech, confusion, seizure or vision loss. Also get help for a new headache after a head injury, a first severe headache after age 50, or a headache pattern that changes sharply. Signs of a serious allergic reaction, including swelling of the face or throat, hives or trouble breathing, are an emergency at any point after a dose.

Further reading on how telehealth programs are structured and priced sits in the site’s Editorial Analysis Archive.

Authoritative sources

• Manufacturer prescribing information for indications, dosing limits, contraindications and interactions.
• MedlinePlus patient drug summary from the National Library of Medicine.
• FDA drug information and safety communications for current regulatory updates.

Educational content, not medical advice. Always consult a qualified clinician before starting, stopping or switching treatment.